Avalon BioVentures — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Arialysarialysrx.comin𝕏Sep 2023 · $58M✓ verified
Arialys Therapeutics develops precision medicines designed to block pathogenic autoantibodies that target brain receptors such as the NMDA receptor, aiming to treat neuropsychiatric disorders driven by autoimmune disease.
BiotechHealthtechLa Jolla, US
Peter Flynn, Ph.D.(Executive Officer, Director)
BoardJay Lichter, Ph.D.(Director)Brian Slingsby, M.D., Ph.D., M.P.H.(Director)Ed Hurwitz(Director)inAshish Xavier, Ph.D.(Director)Tighe Reardon(Executive Officer)
Co-investorsCatalys PacificMPM BioImpact
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.